Cleveland Clinic submits plan for London location

The Cleveland Clinic is seeking approval to build a new hospital in London, which would be its third international facility and first in Europe.

The clinic’s plan is to build a hospital with 205 beds and eight operating rooms in a six-story, 198,000-square-foot building in central London, near Buckingham Palace. The facility would offer general surgery, cardiology and neurology services, but not an emergency department.

“London offers a unique combination of world-leading medical research and some of the best and most respected healthcare professionals,” Cleveland Clinic President and CEO Toby Cosgrove, MD, said in a statement. “Our goal is to complementnot competewith medical offerings available in the London market.”

Cosgrove mentioned he trained in London as a cardiac surgeon.

Cleveland Clinic signed a lease on the London facility in October 2015 for an undisclosed amount, though it could be as high as $23.7 million based on the typical rent for office space in the area, estimated to be between $70 and $120 per square foot by the Cleveland Plain-Dealer.

The plans are now being reviewed by the Westminster City Council.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.